Detection and incidence of drug-induced agranulocytosis in hospital: A prospective analysis from laboratory signals

European Journal of Clinical Pharmacology

Volumn 63, Issue 3, 2007, Pages 221-228

  Tavassoli, N ^a   Duchayne, E ^b   Sadaba, B ^c   Desboeuf, K ^d   Sommet, A ^a   Lapeyre Mestre, M ^a   Muoz, M J ^c   Sie, P ^b   Honorato, J ^c   Montastruc, J L ^a   Bagheri, H ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b CHU PURPAN   (France)

^c Universidad Pública de Navarra   (Spain)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Drug induced agranulocytosis; Laboratory monitoring; Pharmacovigilance; Underreporting rate

Indexed keywords

ALLOPURINOL; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; ANTITHYROID AGENT; AZATHIOPRINE; BISOPROLOL; CARBAMAZEPINE; CARBIMAZOLE; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CLOPIDOGREL; COLCHICINE; FLUINDIONE; FUROSEMIDE; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; LISINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; PANTOPRAZOLE; PIPERACILLIN PLUS TAZOBACTAM; SALAZOSULFAPYRIDINE; TACROLIMUS; TEICOPLANIN; TIAPROFENIC ACID; TICLOPIDINE; UNINDEXED DRUG;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; DISEASE SEVERITY; DRUG INDUCE AGRANULOCYTOSIS; DRUG INDUCED AGRANULOCYTOSIS; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; FEMALE; FRANCE; HEALTH SURVEY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROGNOSIS; SPAIN; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; FEMALE; HUMANS; INCIDENCE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 33846905497     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0242-8     Document Type: Article

References (38)

1. Medina PJ, George JN (2001) Drug-associated blood dyscrasias. Adv Drug React Bull 210:803-806
2. Kaufman DW, Kelly JP, Levy M, Shapiro S (1991) The drug etiology of agranulocytosis and aplastic anemia. Oxford University Press, New York
3. Theophile H, Begaud B, Martin K, Laporte JR, Capella D (2004) Incidence of agranulocytosis in southwest France. Eur J Epidemiol 19:563-565
4. Andrès E, Maloisel F (2006) Idiosyncratic drug-induced agranulocytosis. Rev Med Int 27:209-214
5. Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M (1992) Descriptive epidemiology of agranulocytosis. Arch Intern Med 152:1475-1480
6. Young NS (1994) Agranulocytosis. JAMA 271:935-938
7. Kaufman DW, Kelly JP, Jurgelon JM et al (1996) Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl 60:23-30
8. Julia A, Olona M, Bueno J et al (1991) Drug induced agranulocytosis: pronostic factors in a series of 168 episodes. Br J Haematol 79:366-371
9. Ibanez L, Juan J, Perez E, Carne X, Laporte J-R (1991) Agranulocytosis associated with aprindine and other antiarrhythmic drugs: an epidemiological approach. Eur Heart J 12:639-641
10. Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M, Lundin FE (1993) Nonsteroidal anti-inflammatory drugs and neutropenia. Arch Intern Med 153:2119-2124
11. Rawson NSB, Harding SR, Malcolm E, Lueck L (1998) Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use. J Clin Epidemiol 51:1343-1355
12. Van der Klauw MM, Goudsmit R, Halie MR et al (1999) A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 159:369-374
13. Laporte JR, Capella D, Juan J (1990) Agranulocytosis induced by cinepazide. Eur J Clin Pharmacol 38:387-388
14. Ibanez L, Ballarin E, Perez E, Vidal X, Capella D, Laporte JR (2000) Agranulocytosis induced by pyrithyldione, a sedative hypnotic drug. Eur J Clin Pharmacol 55:761-764
15. Ibanez L, Ballarin E, Vidal X, Laporte JR (2000) Agranulocytosis associated with calcium dobesilate: clinical course and risk estimation with the case-control and the case-population approaches. Eur J Clin Pharmacol 56:763-767
16. Ibanez L, Vidal X, Ballarin E, Laporte JR (2005) Population-based drug-induced agranulocytosis. Arch Intern Med 165:869-874
17. Benichou Ch (1994) Adverse drug reactions: a practical guide to diagnosis and management. Wiley, Chichester
18. No authors listed (1991) Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced cytopenia. Int J Clin Pharmacol Ther Toxicol 29:75-81
19. Cancer Therapy Evaluation Program (2003) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. http://www.ctep.cancer.gov/forms/CTCAEv3. pdf
20. Uppsala Monitoring Centre (2006) The use of the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) system for standardised case causality assessment. http://www.who-umc.org/graphics/4409.pdf
21. Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255-59
22. Anonymous (2006) Dictionnaire VIDAL, 82th edn. OVP, Paris
23. No authors listed (2005) Catálogo de especialidades farmacéuticas. Consejo General de Colegios de Farmacéuticos, Madrid
24. Tubert P, Bégaud B, Péré JC, Haramburu F, Lellouch J (1992) Power and weakness of spontaneous reporting: a probabilistic approach. J Clin Epidemiol 45:283-286
25. Haramburu F (1993) Estimation of under-reporting. Methodological approaches in pharmacoepidemiology: application to spontaneous reporting ARME-P. Elsever, Amsterdam
26. Thürmann P (2001) Methods and systems to detect adverse drug reactions in hospitals. Drug Saf 24:961-968
27. Azaz-Livshits T, Levy M (1998) Computerized surveillance of adverse drug reactions in hospital: a pilot study. Br J Clin Pharmacol 45:309-314
28. Tegeder I, Levy M, Muth-Selbach U (1999) Retrospective analysis of the frequency and recognition of adverse reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 47:557-564
29. Bagheri H, Michel F, Lapeyre-Mestre M et al (2000) Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol 50:479-484
30. Levy M, Azaz-Livshits T, Sadan B et al (1999) Computerized surveillance of adverse reactions in hospital: implementation. Eur J Clin Pharmacol 54:887-892
31. Salame G, Péré JC, Chaslerie A et al (1990) Liver injuries: a prospective study (abstract). J Clin Res Pharmacoepidemiol 4:133
32. Dugué A, Bagheri H, Lapeyre-Mestre M, Tournamille JF et al (2004) Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals. Eur J Clin Pharmacol 60:285-292
33. Andersohn F, Bronder E, Klimpel A, Garbe E (2004) Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin Case-Control Surveillance Study. Am J Hematol 77 :316-318
34. Assurance Maladie en ligne (2006) Les médicaments remboursés en 2003 et 2004 par le régime général d'Assurance maladie. http://www.ameli.fr/244/DOC/2333/article.html
35. IMS (2006) Pharmaceutical market intelligence. http://www.imshealth.com
36. The International Agranulocytosis and Aplastic Anemia Study (1986) Risk of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. JAMA 256:1749-1757
37. Classen DC, Pestotnik SL, Evans RS, Bruke JP (1991) Computerized surveillance of adverse drug events in hospital patients. JAMA 266:2847-2851
38. Bates DW, O'Neil AC, Boyle D, Teich J, Chertow GM, Komaroff AL, Brennan TA (1994) Potential identifiability and preventability of adverse events using information systems. J Am Med Inform Assoc 1:404-411